Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $77,067.37 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 2,503 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $77,067.37. Following the sale, the chief operating officer now owns 203,783 shares of the company’s stock, valued at $6,274,478.57. This represents a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jonathan Young also recently made the following trade(s):

• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.13, for a total transaction of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.57, for a total value of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.15, for a total transaction of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.18, for a total value of $281,800.00.

Akero Therapeutics Trading Down 0.5 %

Shares of AKRO stock opened at $28.89 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The firm has a fifty day moving average price of $30.81 and a 200-day moving average price of $27.13. The company has a market cap of $2.02 billion, a price-to-earnings ratio of -7.70 and a beta of -0.23. Akero Therapeutics, Inc. has a 1 year low of $15.32 and a 1 year high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). As a group, equities analysts predict that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on AKRO shares. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a report on Monday, November 18th. Citigroup assumed coverage on shares of Akero Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $65.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its stake in Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after purchasing an additional 201,225 shares during the last quarter. RTW Investments LP lifted its holdings in shares of Akero Therapeutics by 9.0% in the 3rd quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after acquiring an additional 487,450 shares during the last quarter. Perceptive Advisors LLC lifted its stake in Akero Therapeutics by 8.1% in the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock worth $35,188,000 after purchasing an additional 112,426 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Akero Therapeutics during the 3rd quarter valued at $37,392,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.